



## **ViroGates announces receipt of the first order from Mikkeli Central Hospital in Finland, the first clinical routine customer in Finland and the implementation and first order from a private health clinic in Sweden**

24.11.2020 07:39:51 CET | ViroGates | Company Announcement

**BIRKERØD, DENMARK** - 24 November 2020

ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that it has received an order from a new clinical routine customer in Finland.

The customer is Mikkeli Central Hospital. This customer is the first hospital to use suPARnostic® TurbiLatex in clinical routine in Finland. Mikkeli is the central hospital in Mikkeli and is also serving the uptake population in neighbouring municipalities. The hospital has an uptake population of about 100,000 inhabitants and approx. 200 beds.

The implementation has followed a process of pilot use of the suPARnostic® TurbiLatex product in a large cohort of approx. 1,700 patients and the findings of the study will be published shortly. The Hospital, however, has decided to implement suPARnostic® TurbiLatex immediately to broadly improve triage in the emergency department. The hospital has therefor submitted the first order to ViroGates.

Unrelated to the above, a Swedish provider of health tests, has decided to incorporate suPARnostic® Quick Triage in the standard panel of offerings to its corporate health test clients. The customer offers a range of health tests based on physiological and biological parameters to its clients in Sweden. This account will use suPARnostic® Quick Triage.

**Jakob Knudsen, Chief Executive Officer of ViroGates, says:** *"We are excited to announce our first clinical routine customer in Finland. We have worked with Mikkeli Central Hospital over a period of time to illustrate the value suPARnostic® has in triage in the central hospital system in general. We are happy that this pilot use study has been so convincing, that our customer has decided to implement our products rapidly, and in anticipation of the publication of the outcome. Along with the customer we look forward to the publication of the results and will now get the first commercial shipment sent off, for use on the hospitals' Roche cobas system.*

*Furthermore we, also today, received the first order from a customer from a different segment – the corporate health screening market. This is a new market that has seen the benefits of measuring the inflammation levels of workers in larger organisations in Sweden. We are really excited that this segment is also picking up on the value of suPARnostic®. We believe that this market has a very promising future with more and more people being interested in taking control of their health status and proactively react upon this.*

The announcement can be found at <https://www.virogates.com/investor/announcements>

### **For further information please contact:**

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: [jk@virogates.com](mailto:jk@virogates.com)

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: [per.lonn@vhcorp.se](mailto:per.lonn@vhcorp.se)

**About ViroGates**

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit [www.virogates.com](http://www.virogates.com).

### **About suPAR and suPARnostic®**

suPAR is the biomarker measured by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

### **Disclosure regulation**

*Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.*

### **Contacts**

- Jakob Knudsen, CEO, +45 2226 1355, [jk@virogates.com](mailto:jk@virogates.com)

### **Attachments**

- [20201124-ViroGates Company announcement 24.pdf](#)